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The -defensin antimicrobial peptide family is defined
by a unique tridisulfide array. To test whether this in-
variant structural feature determines -defensin bacte-
ricidal activity, mouse cryptdin-4 (Crp4) tertiary struc-
ture was disrupted by pairs of site-directed Ala for Cys
substitutions. In a series of Crp4 disulfide variants
whose cysteine connectivities were confirmed using
NMR spectroscopy and mass spectrometry, mutagenesis
did not induce loss of function. To the contrary, the in
vitro bactericidal activities of several Crp4 disulfide
variants were equivalent to or greater than those of
native Crp4. Mouse Paneth cell -defensins require the
proteolytic activation of precursors by matrix metallo-
proteinase-7 (MMP-7), prompting an analysis of the rel-
ative sensitivities of native and mutant Crp4 and pro-
Crp4 molecules to degradation by MMP-7. Although
native Crp4 and the -defensin moiety of proCrp4 re-
sisted proteolysis completely, all disulfide variants were
degraded extensively by MMP-7. Crp4 bactericidal ac-
tivity was eliminated by MMP-7 cleavage. Thus, rather
than determining -defensin bactericidal activity, the
Crp4 disulfide arrangement confers essential protection
from degradation by this critical activating proteinase.
The mammalian defensins comprise the -, -, and -defen-
sin families of cationic, Cys-rich antimicrobial peptides, and
each subfamily is characterized by a distinctive tridisulfide
array (1). -Defensins are cationic, amphipathic, 3–4-kDa pep-
tides with a -sheet polypeptide backbone and broad spectrum
antimicrobial activities (1). The consensus -defensin tertiary
structure is established by six cysteines that are spaced in a
pattern that facilitates the formation of invariant disulfide
bonds between CysI-CysVI, CysII-CysIV, and CysIII-CysV (2)
(Fig. 1). These conserved -defensin disulfide pairings have
been inferred to have a role in determining, perhaps critically,
the bactericidal activity of these peptides.
Paneth cell -defensins confer enteric immunity (3) and,
thus, knowledge of determinants of peptide activity and bio-
synthetic regulation will improve the understanding of the role
of these -defensins in mucosal immunity. For example, mouse
Paneth cell -defensins, termed cryptdins (Crps),1 are secreted
into the lumen of small intestinal crypts at concentrations of
25–100 mg/ml, four orders of magnitude greater than their
minimum bactericidal concentrations (4). In mice, Paneth cell
-defensin precursors (proCrps) are processed to their biologi-
cally active forms by specific proteolytic cleavage events cata-
lyzed by matrix metalloproteinase-7 (MMP-7, matrilysin). Dis-
ruption of the MMP-7 gene abrogates proCrp activation,
eliminating the accumulation of functional mature Crp pep-
tides from the small intestine (5). Consequently, MMP-7-null
mice have impaired enteric innate immunity in response to oral
bacterial infection (5). Also, in mice transgenic for the human
Paneth cell -defensin HD5, the minitransgene is expressed
specifically in Paneth cells, and the mice are immune to oral
infection by virulent strains of Salmonella enterica serovar
Typhimurium (serovar Typhimurium) (3).
Here, we report on the role of the disulfide array in the mouse
Paneth cell -defensin cryptdin-4 (Crp4) (6, 7). Paired Ala for Cys
amino acid substitutions in Crp4 were tested for effects on bac-
tericidal activity and resistance to the activating proteinase
MMP-7. Mutations that disrupted disulfide bonds did not inacti-
vate peptide bactericidal activity regardless of position. However,
Crp4 and proCrp4 molecules with disrupted disulfides were pro-
teolyzed extensively by MMP-7, disclosing a critical protective
role for the disulfide array in peptide biosynthesis.
EXPERIMENTAL PROCEDURES
Preparation of Recombinant Crp4 Peptide Variants—Recombinant
Crp4 peptides were expressed in Escherichia coli as N-terminal His6-
tagged fusion proteins from the EcoRI and SalI sites of the pET28a
expression vector (Novagen, Inc., Madison, WI) as described (8, 9). The
Crp4-coding cDNA sequences were amplified using the forward primer
ER1-Met-C4-F (5-GCGCGAATTCATCGAGGGAAGGATGGGTTTGT-
TATGCTATTGT-3) paired with the reverse primer pMALCrp4-R (5-
ATATATGTCGACTCAGCGACAGCAGAGCGTGTACAATAAATG-3)
as reported previously (9). For proCrp4, the forward primer pETPCr4-F
(5-GCGCGAATTCATGGATCCTATCCAA AACACA-3) was paired
with the reverse primer SLpMALCrp4R (5-ATATATGTCGACTGT-
TCAGCGGCGGGGGCAGCAGTACAA-3), corresponding to nucleo-
tides 104–119 and 301–327 in preproCrp4 cDNA (8). The underlined
codons in the forward primers denote Met codons introduced upstream
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of each peptide N terminus to provide a CNBr cleavage site (8, 9). In all
instances, reactions were performed using the GeneAmp PCR Core
Reagents (Applied Biosystems, Foster City, CA) by incubating the re-
action mixture at 94 °C for 5 min followed by successive cycles at 94 °C
for 30 s, 60 °C for 30 s, and 72 °C for 30 s for 30 cycles and then a final
extension reaction at 72 °C for 7 min.
Mutagenesis at Cys Residue Positions—Mutations were introduced
into Crp4 by PCR as described previously (8) in the order described
below. In the first round of mutagenesis the Crp4 construct in pET-28a
(9) was used as template. In PCR reaction number 1, a mutant forward
primer, e.g. Crp4-C11A-F, containing the mutation for peptide residue
position 11 flanked by three natural codons was paired with the reverse
primer T7 terminator (Invitrogen), a downstream sequencing primer in
the pET-28a vector. In PCR reaction number 2, the mutant reverse
primer Crp4-C11A-R, the reverse complement of the mutant forward
primer, was paired with the T7 promoter forward primer, again from
the pET-28a. After amplification at 94 °C for 5 min followed by succes-
sive cycles at 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s for 30
cycles and then a final extension reaction at 72 °C for 7 min, samples of
purified products from reactions number 1 and number 2 were com-
FIG. 1. Recombinant Crp4 and proCrp4 disulfide variants. The primary structures of recombinant Crp4 and proCrp4-(20–94) peptides
prepared and investigated in these studies are aligned in panels A and B, respectively. Numerals above the Crp4 sequence refer to residue positions
in reference to the N-terminal Gly of native Crp4 as residue position number 1. Altered Cys to Ala mutations in Crp4 and proCrp4 peptide variants
are shown in underlined, boldfaced text. Multiple mutation designations used in panels A and B are as follows: C4/29A, C4A/C29A; C6/21A,
C6A/C29A; C11/28A, C11A/C28A; C4/11/28/29A, C4A/C11A/C28A/C29A; all C3A, C4A/C6A/C11A/C21A/C28A/C29A. The disulfide bond designa-
tions used in panel A are as follows: C1-C6, CysI-CysVI; C2-C4, CysII-CysIV; C3-C5, CysIII-CysV. In panel C, 3-g samples of purified recombinant
Crp4 and variants of Crp4 and 6-g samples of proCrp4 and variants were resolved by AU-PAGE and stained with Coomassie Blue. Lane 1, Crp4
(lower left arrow); lane 2, (C4A/C29A)-Crp4; lane 3, (C6A/C21A)-Crp4; lane 4, (C11A/C28A)-Crp4; lane 5, (C4A/C11A/C28A/C29A)-Crp4; lane 6,
(C4A/C6A/C11A/C21A/C28A/C29A)-Crp4; lane 7, proCrp4 (upper right arrowhead); lane 8, (C6/21)-proCrp4; lane 9, (C4/11/28/29)-proCrp4; lane 10,
(C4A/C6A/C11A/C21A/C28A/C29A)-proCrp4.
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bined as templates in PCR reaction number 3 using the T7 promoter
and terminator primers as amplimers. All mutated Crp4 templates
were cloned in pCR-2.1 TOPO, verified by DNA sequencing, excised
with SalI and EcoRI, subcloned into pET28a plasmid DNA (Novagen,
Inc.), and transformed into E. coli BL21(DE3)-CodonPlus-RIL cells
(Stratagene) for recombinant expression. The underlined codons in the
forward primers denote Met codons introduced upstream of each pep-
tide N terminus to provide a CNBr cleavage site (8, 9).
Mutant Crp4 peptides with additional Ala for Cys substitutions were
prepared by accumulating mutations in modified templates as follows.
For (C11A)-Crp4, the pET28-Crp4 construct was used as the template
in reaction number 1 with the forward primer Crp4-C11A-F (5-AAAG-
GACACGCCAAAAGAGGA-3) and the reverse primer Crp4-C11A-R
(5-TCCTCTTTTGGCGTGTCCTTT-3) paired with the T7 promoter
and the terminator primers (pET T7 primers), with samples of these
products used as a combined template for full-length product amplifi-
cation with pET T7 primers. For (C21A)-Crp4, the pET28-Crp4 con-
struct template was amplified with the Crp4-C21A-F forward primer
(5-CGTGGGACTGCTGGAATACGA-3) and the Crp4-C21A-R reverse
primer (5-TCGTATTCCAGCAGTCCCACG-3) paired with the pET T7
primers, and the final products were prepared as described above. For
(C11A/C21A)-Crp4, the full-length (C11A)-Crp4 amplification product
was amplified with Crp4-C21A-F and Crp4-C21A-R and the pET T7
primers as described above. For (C6A/C21A)-Crp4, the full-length
(C21A)-Crp4 product was amplified with the Crp4-C6A-F forward
primer (5-GAATTCATGGGTTTGTTATGCTATGCTAGA-3) paired
with pMALCrp4-R. For (C11A/C28A)-Crp4, the full-length (C11A)-Crp4
product was amplified with the Crp4-C28A-R reverse primer (5-GTC-
GACTCATCAGCGGCGGGGACAGGCGTA-3) to amplify the full-
length product. To prepare (C4A/C29A)-Crp4, the Crp4-coding pET28a
was amplified using the Crp4-C4A-F forward primer (5-ACACAC-
GAATTCATGGGTTTGTTAGCCTATTGT-3) and the Crp4-C29A-R re-
verse primer (5-ACACACGTCGACTCATCAGCGGCGGGGTGCGCA-
3). For (C4A/C11A/C28A/C29A)-Crp4, the full-length (C11A)-Crp4
amplification product was used as the template with the Crp4-C4A-F
forward primer and the Crp4-C28AC29A-R reverse primer (5-GTC-
GACTCATCAGCGGCGGGGTGCGGCGTA-3). To mutagenize all Cys
positions in Crp4 (Cys4, Cys6, Cys11, Cys21, Cys28, and Cys29) the full-
length (C11A/C21A)-Crp4 PCR product was amplified with the Crp4-
C4AC6A-F forward primer (5-GAATTCATGGGTTTGTTAGCCTAT-
GCTAGA-3) and the Crp4-C28AC29A-R reverse primer. Boldfaced
residues in the primer sequences above denote codons for alanines.
To prepare (C4A/C11A/C28A/C29A)-proCrp4 and (C4A/C6A/C11A/
C21A/C28A/C29A)-proCrp4, the peptide-coding regions of the (C4A/
C11A/C28A/C29A)- and (C4A/C6A/C11A/C21A/C28A/C29A)-Crp4
pET28 constructs were amplified with the PC4Cod54/63-F forward
primer (5-CTTCATGAAAAATCTTTGAGAGGTTTGTTA-3) and the
Crp4-C28AC29A-R reverse primer, and the proCrp4 prosegment coding
region was amplified from a proCrp4 pET-28a construct (8) using the
pETPCr4-F forward primer (5-GCGCGAATTCATGGATCCTATC-
CAAAACACA-3) with the PC4Cod54/63-R reverse primer (5-
TAACAAACCTCTCAAAGATTTTTCATGAAG-3). The underlined
codon in the forward primer denotes a Met codon introduced upstream
of the peptide N terminus to provide a CNBr cleavage site (8, 9).
Samples of these reactions were used as a combined template with
pETPCr4-F and Crp4-C28AC29A-R to prepare the full-length proCrp4
molecules with mutated disulfide bonds.
Purification of Recombinant Crp4 Proteins—Recombinant proteins
were expressed and purified as His-tagged Crp4 fusion peptides as
described (8). Briefly, recombinant proteins were expressed at 37 °C in
Terrific Broth medium by induction with 0.1 mM isopropyl--D-1-thio-
galactopyranoside for 6 h at 37 °C, cells were lysed by sonication in 6 M
FIG. 2. NMR characterization of Crp4 and disulfide mutants. Panel A shows the amide region of the one-dimensional spectra. Selected
upfield (Cys4) and downfield (Arg18 and Cys29) NH signals are labeled for native Crp4 and (C6A/C21A)-Crp4 (Crp4C6/21A), illustrating the
excellent signal dispersion characteristic of folded proteins. Panel B shows H secondary shifts for each residue in the native and disulfide deficient
peptides. Arrows indicate regions of the -sheet previously identified in the solution structure of a typical -defensin, RK-1 (23). Native Crp4 and
(C6A/C21A)-Crp4 display stretches of consecutive H secondary shifts with values 0.1 ppm in these regions, strongly indicating that the -sheet
structural elements are also present in these two peptides. By contrast the other mutants have poor dispersion and H secondary shifts typically
0.1 ppm, indicative of random coil structure. The asterisks indicate residues whose NH signals are broadened beyond detection in the spectrum of
(C6A/C21A)-Crp4. Crp4C4/29A, (C4A/C29A)-Crp4; Crp4C11/28A, (C11A/C28A)-Crp4; Crp4C4/11/28/29A, (C4A/C11A/C28A/C29A)-Crp4.
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guanidine-HCl in 100 mM Tris-Cl (pH 8.1), and the soluble protein
fraction was clarified by centrifugation (8–10). His-tagged Crp4 fusion
peptides were purified using nickel-nitrilotriacetic acid (Qiagen) resin
affinity chromatography (8). After CNBr cleavage, Crp4 peptides were
purified by C18 reverse-phase high performance liquid chromatography
(RP-HPLC) and quantitated by bicinchoninic acid (Pierce), and the
molecular masses of the purified peptides were determined using ma-
trix-assisted laser desorption ionization mode mass spectrometry (Voy-
ager-DE MALDI-TOF, PE-Biosystems, Foster City, CA) in the Mass
Spectroscopy Facility, Department of Chemistry, University of Califor-
nia, Irvine, CA.
NMR Spectroscopy—Samples of Crp4 and the mutants used for NMR
analysis contained 2 mg of Crp4, 0.6 mg of (C6A/C21A)-Crp4, and 0.3
mg of the other mutants dissolved in 0.5 ml of 95% H2O/5% D2O at pH
4. One-dimensional and two-dimensional total correlation spectroscopy
with a MLEV17 mixing time of 80 ms and two-dimensional nuclear
Overhauser effect spectroscopy spectra with a mixing time of 200 ms
were recorded for all analogues on a Bruker DMX 750 MHz spectrom-
eter at 298 K. In all experiments, the carrier frequency was set at the
center of the spectrum on the solvent signal, and all spectra were
recorded in phase-sensitive mode using the time-proportional phase
increment method. Solvent suppression was achieved by a modified
WATERGATE sequence. Two-dimensional spectra collected with
4000 data points in the f2 dimension and 512 increments on the f1
dimension over a spectral width corresponding to 12 ppm. Resonance
assignments were achieved by standard sequential assignment
strategies (11).
Bactericidal Peptide Assays—Recombinant peptides were tested for
microbicidal activity against E. coli ML35, wild-type serovar Typhi-
murium strains CS022, JSG210, and 14082 (from Dr. Samuel I. Miller,
University of Washington), Vibrio cholerae, Staphylococcus aureus
710a, and Listeria monocytogenes 104035 as described (12). Bacteria
(5  106 colony forming units (CFU) per milliliter), resuspended in 10
mM PIPES (pH 7.4) supplemented with 0.01 volume of trypticase soy
broth, were incubated with test peptides in 50 l for 1 h at 37 °C, and
surviving bacteria were counted (CFU/ml) after overnight growth on
semi-solid media (8, 9).
Cleavage of Crp4 and proCrp4 Disulfide Variants with MMP-7 in
Vitro—Recombinant Crp4, proCrp4, and variants with site-directed
mutations in the disulfide array were digested with MMP-7 and ana-
lyzed for proteolysis by AU-PAGE, and samples of the proteolytic di-
gests were tested in bactericidal peptide assays and analyzed by N-
terminal sequencing by Edman degradation as described previously (8).
Samples (11 g) of proCrp4 and all proCrp4 variants, as well as 5-g
samples of Crp4 and variants, were incubated with an activated recom-
binant human MMP-7 (0.31.0 g) catalytic domain (Calbiochem, La
Jolla, CA) in buffer containing 10 mM HEPES (pH 7.4), 150 mM NaCl,
and 5 mM CaCl2 for 18–24 h at 37 °C (8). Equimolar samples of all
digests were analyzed by AU-PAGE, and 3-g quantities of complete
digests were subjected to five or more cycles of Edman degradation in
the University of California, Irvine Biomedical Protein and Mass Spec-
trometry Resource Facility.
The biological effects of MMP-7-mediated proteolysis of Crp4 mol-
ecules with mutations in the disulfide array was assayed by conduct-
ing bactericidal peptide assays as above. Bacterial target cells con-
sisting of exponentially growing bacteria (1  106 CFU/ml) were
incubated with equimolar quantities (0 to 20 g/ml) of Crp4 or pro-
Crp4 peptide variants that had been incubated overnight at 37 °C
with or without MMP-7.
FIG. 3. Crp4 disulfide variants are bactericidal. Exponentially growing V. cholerae (A), E. coli ML 35 (B), S. aureus (C), and L. mono-
cytogenes (D) were exposed to the peptide concentrations shown in 50 l of 10 mM PIPES (pH 7.4) and 1% trypticase soy broth for 1 h at 37 °C
(see “Experimental Procedures”). Following exposure, bacteria were plated on semi-solid media and incubated for 16 h at 37 °C. Surviving bacteria
were quantitated (CFU/ml) for each peptide concentration. Bacterial counts below 1  103 CFU/ml indicate that no surviving colonies were
detected. Symbols are as follows: , Crp4; , (C6A/C21A)-Crp4; ƒ, (C11A/C28A)-Crp4; E, (C4A/C11A/C28A/C29A)-Crp4; and f,
(C4A/C6A/C11A/C21A/C28A/C29A)-Crp4.
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RESULTS
Mutagenesis of the Crp4 Disulfide Array—Recombinant Crp4
variants with site-directed mutations in the tridisulfide array
(Fig. 1A) were prepared by expression in E. coli using the
pET-28 vector system (8). As shown in Fig. 1, Crp4 vari-
ants included molecules null for the following: (a) individual
CysI-CysVI, CysII-CysIV, or CysIII-CysV disulfides; (b) both
the CysI-CysVI and CysIII-CysV bonds; and (c) a Crp4 peptide
with all Cys residues converted to Ala and, thus, disulfide-null.
All variant Crp4 peptides were purified to homogeneity by
RP-HPLC as verified by analytical RP-HPLC (not shown) and
AU-PAGE analyses in which the peptides migrated as expected
relative to native Crp4 (Fig. 1C) (8). Alkylation of -defensins
disrupts -sheet structure, linearizing the molecule and reduc-
ing its mobility in AU-PAGE (13). Similarly, the mobility of
these variant Crp4 molecules was diminished with increased
numbers of disrupted disulfides (Fig. 1C).
A series of one-dimensional and two-dimensional total cor-
relation spectroscopy and nuclear Overhauser effect spectros-
copy NMR spectra was recorded to assess the structural integ-
rity of recombinant Crp4 and the disulfide-deficient variants.
The two-dimensional spectra were sequentially assigned and
used to derive chemical shifts for the backbone protons, which
are a sensitive monitor of structure as summarized in Fig. 2.
Native Crp4 and the C6A/C21A variant have widely dispersed
amide signals characteristic of well folded peptides (Fig. 2A).
On the other hand, the amide signals for the C4A/C29A, C11A/
C28A, and C4A/C11A/C28A/C29A variants have a narrow am-
ide dispersion typical of random coil conformations. Confirma-
tion that the native peptide and the C6A/C21A variant are well
folded and that the other variants are not is evident from the
H secondary shifts (Fig. 2B), i.e. the differences between the
observed chemical shifts of a given amino acid and those for the
corresponding residue in a random coil peptide. The presence of
several consecutive residues with positive H secondary shifts
of magnitude0.1 ppm provides a strong indication of -strand
structure. Such regions are seen in Crp4 and in the C6A/C21A
mutant and correspond to the regions comprising a triple-
stranded -sheet typically seen in other -defensins (Fig. 2B,
arrows). By contrast, the C4A/C29A, C11A/C28A, and C4A/
C11A/C28A/C29A Crp4 mutants have small secondary shifts
characteristic of random coil peptides. These trends correspond
well with the gel migration data in Fig. 1C, where the C6A/
C21A variant migrates similarly to the native peptide, but the
others have diminished mobility as would be expected for dis-
ordered peptides.
The -Defensin Disulfide Array Does Not Determine Crp4
Bactericidal Activity in Vitro—To investigate the role of the
Crp4 disulfide array, we assayed the in vitro bactericidal
activities of Crp4 disulfide mutants against several bacterial
species in relation to native Crp4 (Fig. 3). The overall bacte-
ricidal activities of Crp4 and Cys 3 Ala Crp4 variants were
similar, although not identical, with all of the peptides re-
ducing bacterial cell survival by at least 1000-fold at concen-
trations at or below 25 g/ml (Figs. 3 and 4 and data not
shown). Because differences in peptide bactericidal activities
become more apparent in assays against species with inher-
ently lower antimicrobial peptide sensitivities, the peptides
were tested against strains of wild-type serovar Typhi-
murium, which has low -defensin susceptibility relative to
other species of bacteria (14–17). Three disulfide mutants,
the C6A/C21A, C4A/C11A/C28A/C29A, and C4A/C6A/C11A/
C21A/C28A/C29A variants of Crp4, were consistently more
active than native Crp4 against wild-type serovar Typhi-
murium (Fig. 4). Therefore, Crp4 bactericidal activity is in-
dependent of disulfide mutagenesis with molecules lacking
more than one disulfide bond showing enhanced microbicidal
activities, although the dose-response curves of certain pep-
tides varied modestly (Figs. 3 and 4). Because mutagenesis at
Crp4 disulfides did not induce loss of function, we considered
alternative roles for the disulfide array, including protection
of the peptide from degradation by the activating proteinase.
Disulfide Bonds Protect Crp4 from Proteolysis by MMP-7—
Production of functional mouse Paneth cell -defensins re-
quires that MMP-7 mediate proteolytic cleavage of inactive
proCrps (5). To test whether the disulfide array protects the
Crp4 moiety from MMP-7 proteolysis during activation, we
first assayed for cleavage products of native and mutant Crp4
molecules exposed to MMP-7 (Fig. 5). As reported previously
(8), native Crp4 was completely resistant to MMP-7 in vitro,
but all Crp4 peptides with disrupted cystine pairings were
degraded extensively (Fig. 5A). As expected, MMP-7 activated
native proCrp4 as shown by AU-PAGE analyses (Fig. 5A) and
in functional assays (Fig. 6A, and see below). Consistent with
peptide structures, the major degradation products detected on
the gels (Fig. 5A) all have increased mobilities relative to the
uncleaved disulfide-deficient peptide, except for (C6A/C21A)-
Crp4. Its high intrinsic mobility is due to the loss of native-like
globular structure on proteolysis, whereas the degradation
products of the other, random coil peptide variants increased in
mobility.
N-terminal sequencing of MMP-7 peptide digests detected
four major cleavage sites in peptides lacking one disulfide bond,
FIG. 4. Bactericidal activity of Crp4 and Crp4 disulfide vari-
ants against serovar Typhimurium. Exponentially growing wild-
type serovar Typhimurium strains CS022 (A), JSG210 (B), and 14082
(C) were exposed to the peptides, and the surviving bacterial cells were
quantitated (CFU/ml) (Fig. 3). Symbols are as follows: , Crp4; ,
(C6A/C21A)-Crp4; ƒ, (C11A/C28A)-Crp4; E, (C4A/C11A/C28A/C29A)-
Crp4; and f, (C4A/C6A/C11A/C21A/C28A/C29A)-Crp4. Note that the
(C4A/C11A/C28A/C29A)-Crp4 and (C4A/C6A/C11A/C21A/C28A/C29A)-
Crp4 variants are more bactericidal against this generally defensin-
resistant species.
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seven sites in (C4A/C11A/C28A/C29A)-Crp4, and six in (C4A/
C6A/C11A/C21A/C28A/C29A)-Crp4 (Fig 5B), showing that the
Crp4 disulfide array provided protection against proteolytic
degradation. (C4A/29A)-Crp4 also was cleaved by MMP-7 as
judged by its AU-PAGE mobility after enzyme treatment (Fig.
5A), but C4A/C29A peptide digests were not sequenced.
MALDI-TOF MS analysis of MMP-7 digests of (C4A/C29A)-
Crp4 identified peptide masses of 1868.2, 3342.9, and 3527.2
that are consistent with cleavage events at Leu22Leu3,
Ala42Tyr5, and Arg162Val17. Although cleavage at these sites
is evident, we cannot exclude the possibility of additional cleav-
age sites in (C4A/C29A)-Crp4 that were not detected by this
approach. Thus, a predicted outcome of -defensin disulfide
mutagenesis in vivo would be peptide degradation during pre-
cursor activation.
Proteolysis of Crp4 Disulfide Variants Abolishes Bactericidal
Activity—The bactericidal activities of (C4/11/28/29/A)-Crp4
and (C4A/C6A/C11A/C21A/C28A/C29A)-Crp4 were eliminated
by proteolysis with MMP-7. (C6A/C21A)-Crp4 and (C11A/
C28A)-Crp4 containing CysI-CysVI plus CysIII-CysV and CysI-
CysVI plus CysII-CysIV connectivities, respectively, were di-
gested extensively by MMP-7 (Fig. 5B), yet the cleaved peptides
retained activity similar to that of native Crp4 (Fig. 6B). Thus,
certain proteolytic fragments of these Crp4 variants are bacte-
ricidal despite the hydrolysis of four peptide bonds. In the
preliminary RP-HPLC of MMP-7-digested (C11A/C28A)-Crp4
separations, bactericidal activity was isolated in a single frac-
tion coinciding with a prominent HPLC peak containing pep-
tide fragments with masses of 3125, 2249, and 878 atomic mass
units. When combined with N-terminal sequence analysis of
those fractions (not shown), we deduced that the active fraction
consisted of two Crp4 fragments, Leu3–Gly22 (2250.6 atomic
mass units) and Leu26–Arg32 (878.0 atomic mass units) joined
by the CI-CVI disulfide bond to give a mass of 3125 (not shown).
As before (8, 9), MMP-7 activated native proCrp4 (Fig. 6A) and
did not affect Crp4 bactericidal activity as its MMP-7 resist-
ance predicted (Fig. 6A, and see Fig. 5). In contrast, proteolysis
of (C4A/C11A/C28A/C29A)-Crp4 and (C4A/C6A/C11A/C21A/
C28A/C29A)-Crp4 by MMP-7 (Fig. 5B) abolished in vitro bac-
tericidal activity (Fig. 6C, open symbols). These results show
FIG. 5. MMP-7 degrades Crp4 vari-
ants with disrupted disulfide arrays.
Samples of Crp4 (5 g), proCrp4 (11 g),
and Crp4 disulfide variants were incu-
bated overnight at 37 °C in the presence
or absence of MMP-7, the proCrp-activat-
ing enzyme. In panel A, 5-g samples of
the peptides shown were incubated with
() or without () MMP-7, subjected to
analytical AU-PAGE, and stained with
Coomassie Blue (see “Experimental Pro-
cedures”). Upper arrow denotes proCrp4,
and lower arrow denotes Crp4. Stained
MMP-7 is evident below the positive ()
symbols near the gel origins. C4/C29A,
(C4A/C29A)-Crp4; C6/21A, (C6A/C21A)-
Crp4; C11/28A, (C11A/C28A)-Crp4;
C4/11/28/29A, (C4A/C11A/C28A/C29A)-
Crp4; 6C/A, (C4A/C6A/C11A/C21A/C28A/
C29A)-Crp4. In panel B, samples of Crp4
and Crp4 variants (3 g) incubated
overnight with 0.5-mol equivalents of
MMP-7 (panel A) were analyzed by five
cycles of N-terminal peptide sequencing.
The primary cleavage sites disclosed by
protein sequencing are noted by inverted
triangles () that interrupt the individual
sequences, and the N termini detected at
lower levels are depicted by downward
arrows (2). The characteristic -defensin
cysteine connectivities are shown in Crp4
and the mutant peptides. Positions at
which Cys to Ala mutations occur are
shown in boldfaced type. Note that
MMP-7 does not cleave native Crp4; clea-
vage of native proCrp4 occurred as char-
acterized previously (8). (C6/21A)Crp4,
(C6A/C21A)-Crp4; (C11/28A)Crp4, (C11-
A/C28A)-Crp4; (C4/11/28/29A)Crp4, (C4-
A/C11A/C28A/C29A)-Crp4; (all C3A)C-
rp4, (C4A/C6A/C11A/C21A/C28A/C29A)-
Crp4.
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that Crp4 in vitro bactericidal activity is independent of the
disulfide array and that tertiary structure protects Crp4 from
proteolysis that would destroy its activity. To evaluate that
possibility more directly in the context of the biosynthetic path-
way, we analyzed the proteolytic stability of proCrp4 mutants
with disrupted disulfide arrays (Fig. 1B) in in vitro activation
reactions catalyzed by MMP-7.
Disulfide Bonds Protect the proCrp4 -Defensin Region from
Degradation by MMP-7—To test whether the -defensin disul-
fide array protects against MMP-7-mediated proteolysis of the
Crp4 precursor, three proCrp4 molecules with paired Ala for
Cys substitutions (Fig. 1B) were prepared and exposed to
MMP-7 (Fig. 7). When native proCrp4 was incubated with
MMP-7 as before, the Crp4 peptide region of the precursor was
protected fully during in vitro activation (Fig. 7, A and B). On
the other hand, (C6A/C21A)-, (C4A/C11A/C28A/C29A)-, and
(C4A/C6A/C11A/C21A/C28A/C29A)-proCrp4 were degraded by
MMP-7 as evident by the nearly complete absence of processing
products comigrating with Crp4 (Fig. 7A) and the detection of
four cleavage sites within the defensin moiety (Fig 7B). Proc-
essing events at Ser432Ile44, Ala532Leu54, and Ser582Leu59
(8) occurred normally in the proCrp4 proregion (Fig. 7B) re-
gardless of the status of the disulfide array, although differ-
ences in the kinetics of MMP-7 processing of proCrp4 mutants
is a possibility. AU-PAGE analysis suggested that (C6A/C21A)-
proCrp4 was less extensively degraded, but N-terminal se-
quencing of digests showed that it was cleaved at the same
sites as (C4A/C6A/C11A/C21A/C28A/C29A)-proCrp4 (Fig 7B),
namely at Leu622Leu63, Cys642Tyr65, Gly842Ile85, and
Phe872Leu88. Except for cleavage at Gly842Ile85, MMP-7 di-
gestion of disulfide-deficient and alkylated proCrp4 molecules
occured at the same sites (8). Perhaps the visible MMP-7 cleav-
age product of (C6A/C21A)-proCrp4 (Fig. 7A) represents two or
more fragments that remain connected by disulfide bonds.
Also, disulfide mutagenesis resulted in more extensive degra-
dation of Crp4 mutants than of the corresponding variant pre-
cursors (compare Figs. 5B and 7B) in that Crp4 cleavage sites
corresponding to (Cys/Ala)832Gly84 and Arg862Phe87 were
not detected at those positions in proCrp4, perhaps because the
Crp4 proregion blocks access to those residue positions.
DISCUSSION
The tridisulfide array is a universal and defining feature of
the -defensins (1, 2, 18, 19), but Crp4 bactericidal activity does
not require that the array be intact (Figs. 3 and 4). Similarly
unanticipated were results showing that Crp4 variants lacking
two or three disulfide bonds were more bactericidal against
serovar Typhimurium than the parent molecule (Fig. 4). All
Crp4 and proCrp4 disulfide mutants were degraded by MMP-7
at several internal positions as determined by N-terminal pep-
tide sequence analysis (Figs. 5B and 7B), from which we con-
clude that the disulfide array protects the Crp4 -defensin
moiety during activating proteolysis. Although these studies
have focused on the mouse Paneth cell pro--defensin process-
ing enzyme (5, 20), similar findings have been observed for
corresponding mutations in RMAD-4 and RED-4, myeloid and
Paneth cell -defensins, respectively (21, 22), from rhesus ma-
caque (not shown). We speculate that the disulfide array also
may protect -defensins from degradation in phagolysosomes,
after release into the small intestinal lumen or in the extracel-
lular environment at sites of inflammation.
Of the one-, two-, and three-disulfide Crp4 mutants, C6A/
C21A adopts the most native-like structure and is the variant
most resistant to MMP-7 induced degradation. If C6A/C21A so
resembles native structure, why is it susceptible to proteolysis
at all when Crp4 is completely resistant? The answer appears
to be due to the enhanced molecular flexibility of this mutant
relative to Crp4. Evidence for this possibility may be seen in
the significantly broadened NMR signals for all of the amide
protons in the C6A/C21A mutant relative the native peptide
(compare the upper two traces in Fig. 2A) and in the reduced
size of H secondary shifts (compare the upper two traces in
Fig. 2B). Signal broadening is particularly acute at residues
6–8 and 25–26, and the H signals for these residues are
broadened beyond detection in (C6A/C21A)-Crp4. The en-
hanced mobility near Cys6 reflects the removal of a cross-
linking disulfide bond and potential disruption of the first
strand of the triple-stranded -sheet, whereas the broadening
at Phe25-Leu26 is associated with an extended hairpin turn
between the second and third -strands. This turn appears to
be one of the major sites for proteolytic degradation of the
mutant peptide with three cleavages occurring nearby, includ-
ing one directly at the Phe25-Leu26 peptide bond. In the struc-
ture of the rabbit kidney -defensin RK-1 (23), this hairpin
turn is relatively solvent-exposed and, by homology, is pre-
dicted to be exposed similarly in native Crp4 and more so in
FIG. 6. MMP-7-mediated proteolysis abolishes the bactericidal
activity of Crp4 disulfide mutants. Equimolar quantities of Crp4,
proCrp4, and Crp4 disulfide variants were incubated overnight at 37 °C
in the presence or absence of 0.5-mol quantities of MMP-7, and equi-
molar quantities of all digests were assayed for bactericidal activity
against L. monocytogenes. In all panels, filled symbols denote samples
not incubated with MMP-7, and open symbols denote samples exposed
to MMP-7. A, , Crp4 without MMP-7; E, Crp4 with MMP-7; , pro-
Crp4 without MMP-7; and ƒ, proCrp4 with MMP7. B, , (C6A/C21A)-
Crp4 (C6/21A) without MMP-7; E, (C6A/C21A)-Crp4 (C6/21A) with
MMP-7; , (C11A/C28A)-Crp4 (C11/28A) without MMP-7; ƒ, (C11A/
C28A)-Crp4 (C11/28A) with MMP-7. C, , (C4A/C11A/C28A/C29A)-
Crp4 (C4/11/28/29A) without MMP-7; E, (C4/11/28/29)-Crp4 (C4/11/28/
29A) with MMP-7; , (C4A/C6A/C11A/C21A/C28A/C29A)-Crp4
(6CA) without MMP-7; ƒ, (C4A/C6A/C11A/C21A/C28A/C29A)-Crp4
(6CA) with MMP-7. Note that MMP-7 proteolysis eliminates the bacte-
ricidal activity of (C4/11/28/29)-Crp4 and (C4A/C6A/C11A/C21A/
C28A/C29A)-Crp4.
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(C6A/C21A)-Crp4, where a disulfide bond that tethers this
region to the molecular core is absent. Overall, RK-1 and Crp4
have similarly folded structures (not shown), even though their
primary structures are quite different. Relative to Crp4, RK-1
contains two additional residues between CysIV and CysV, i.e.
between strands 2 and 3. Possibly, the structure of the turn
between these two strands would be less extended in Crp4 than
in RK-1, but residues in the turn still would be solvent-acces-
sible and a major site of proteolytic degradation. The enhanced
flexibility of the (C6A/C21A)-Crp4 mutant presumably facili-
tates access to the enzyme active site, thus increasing the
degree of proteolysis.
The disulfide connectivities of Crp4 variants with just a
single disrupted disulfide, C4A/29A, C6A/21A, and C11A/28A,
were analyzed by MALDI-TOF MS after digestion with MMP-7
(see Fig. 5). For (C11A/C28A)-Crp4, the only disulfide connec-
tivities consistent with the detected peptide masses of 2250.6,
878.0, 3110.4, 1868.2, 3310.9, and 2837.3 atomic mass units are
the predicted CysI-CysVI and CysII-CysIV bonds, confirming the
correct pairings for this peptide. On the basis of similar find-
ings, we could exclude the possibility of CysI-CysIII and CysV-
CysVI disulfide pairings in (C6A/C21A)-Crp4 as well as CysII-
CysIII and CysIV-CysV disulfide bonds in (C4A/C29A)-Crp4,
because no peptide masses consistent with those respective
bonding patterns were detected. However, MALDI-TOF MS
analysis of (C6A/C21A)-Crp4 MMP-7 digests was unable to
distinguish correct CysI-CysVI and CysIII-CysV bond pairings
from a possible CysI-CV and CysIII-CysVI folded variant. Simi-
larly, we could not differentiate between correct CysII-CysIV
and CysIII-CysV connectivities in (C4A/C29A)-Crp4 from a pos-
sible CysII-CysV and CysIII-CysIV misfolded variant. Thus, in
the case of these two mutants, the relation of peptide tertiary
structure to activity is uncertain. Nevertheless, the disulfide
pairings of (C11A/C28A)-Crp4, (C4A/C11A/C28A/C29A)-Crp4
with a solitary CysII-CysIV bond, and disulfide-null (C4A/C6A/
C11A/C21A/C28A/C29A)-Crp4 are unambiguous.
Alterations in the tridisulfide array of -defensin hBD-3
also have little effect on its microbicidal activity (24). Although -
and -defensins both have six Cys residues that form specific and
invariant disulfide bond pairings (2, 25), the spacing of - and
-defensin cysteines and their Cys-Cys pairings differ, and they
have markedly different precursor structures. The -defensin
cystine connectivities are CysI-CysVI, CysII-CysIV, and CysIII-
CysV, and the pairings of -defensins are CysI-CysV, CysII-CysIV,
and CysIII-CysVI, yet the peptides have similar folded conforma-
tions (26–31). Of the six hBD-3 variants with mispaired Cys
FIG. 7. MMP-7-mediated proteolysis
of proCrp4 disulfide variants. Sam-
ples (11 g) of proCrp4 mutants (Fig. 1B)
were incubated overnight at 37 °C in the
presence or absence of MMP-7 and ana-
lyzed in AU-PAGE and by N-terminal se-
quence analysis as in Fig. 5. In panel
A,11-g samples of the peptides shown
were subjected to analytical acid-urea
PAGE with () or without () incubation
with MMP-7 and stained with Coomassie
Blue (see “Experimental and Proce-
dures”). Upper arrow denotes the position
of native proCrp4, lower arrow denotes
Crp4, and arrowhead at top indicates the
position of MMP-7. C6/21A, C6A/C21A;
C4/11/28/29, C4A/C11A/C28A/C29A;
6C/A, C4A/C6A/C11A/C21A/C29A/C29A.
In panel B, 3-g samples of proCrp4 and
proCrp4 variants incubated overnight
with 0.5-mol equivalents of MMP-7 (panel
A) were analyzed by five cycles of N-t-
erminal peptide sequencing. MMP-7 clea-
vage sites detected in the Crp4 proregion
are depicted by downward arrows (2),
and sites within the -defensin regions of
proCrp4 mutants are noted by inverted
triangles () that interrupt the individual
sequences. The -defensin tridisulfide
array is shown above the native proCrp4
sequence and is as predicted for the mu-
tant proCrp4 molecules. Positions at
which Cys to Ala mutations occur in Crp4
are shown in boldfaced type. Note that
MMP-7 does not cleave within the -d-
efensin region of native proCrp4.
Numerals below the (C4A/C6A/C11A/C-
21A/C28A/C29A)-proCrp4 sequence ((all
C3A)-proCrp4) refer to residue positions
numbered in relation to the initiating Met
position in preproCrp4 as residue number
1. Except for the new site detected in
(C4A/C6A/C11A/C21A/C28A/C29A)-pro-
Crp4 ((all C3A)-proCrp4) at Gly842Ile85,
the cleavage sites in this sequence are the
same as those detected in similar analy-
ses of alkylated proCrp4 (8). (C6/21A)-
proCrp4, (C6A/C21A)-proCrp4; (C4/11/28/
29A)-proCrp4, (C4A/C11A/C28A/C29A)-
proCrp4.
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connectivities analyzed (32), the microbicidal activities of native
hBD-3, mispaired variants, and disulfide-null hBD-3 were the
same (24, 32). Similarly, the bactericidal activity of bovine -de-
fensin BNBD-12 against E. coli was also independent of the
disulfide array (33). The possible role of -defensin disulfide
connectivities in conferring resistance to proteolysis is unknown
to our knowledge, perhaps because the mechanisms of -defensin
posttranslational processing remain obscure.
Studies with model membranes support the view that Pan-
eth cell and myeloid -defensins kill their targets by permeabi-
lizing the cell envelope, thus leading to dissipation of electro-
chemical gradients, although the mechanisms of individual
peptides often differ (19, 34). Mouse Crp4 induces graded leak-
age from quenched fluorophore-loaded large unilamellar vesi-
cles (9, 10, 35, 36), and preliminary results show that the Crp4
disulfide variants described here induce large unilamellar ves-
icle leakage by the same mechanism and at levels correspond-
ing to their relative bactericidal activities.2 Although the disul-
fide array has been thought to facilitate peptide-membrane
interactions by maintaining a constrained amphipathic -sheet
structure, those interactions clearly are independent of disul-
fide bonding. Perhaps the disordered, random coil structures of
the disulfide variants in aqueous solution (Fig. 2) assume the
-sheet structure of disulfide-stabilized Crp4 when in hydro-
phobic environments that mimic the lipid-water interface at
the membrane surface. Alternatively, in the absence of con-
straints imposed by the disulfide array, the Crp4 molecule may
adopt an unrelated configuration that retains amphipathicity
and membrane-disruptive behavior.
Transcripts coding for -defensins with mutations at disul-
fide bonds accumulate in mouse small bowel. For example,
C57BL/6 mouse small intestine expresses at least 12 -defen-
sin genes with mutations at varied Cys residue positions. For
example, certain mutations are predicted to disrupt the CysI-
CysVI disulfide bond, including (C6Y)-Crp (GenBankTM acc-
ession number AV070313) and two different (C6F)-Crps (AV-
064537 and AV061023). An additional (C6F)-Crp mutant also
has an Arg35 to Cys substitution that could enable the forma-
tion of an alternative CysI-CysVI bond (AV070855). Double mu-
tants of the CysI-CysVI linkage also exist as exemplified by
(C1W/C6F)-Crp (AV067626) and (C1S/C6F)-Crp (AV067447).
Three different (C5W)-Crp mutant peptides would disrupt the
CysIII-CysV bond (AV064900, AV070633, and AV066474), and a
(C4F)-Crp peptide would lack the CysII-CysIV disulfide (AV-
065642). In addition to these predicted single disulfide bond
disruptions, (C1S/C2S/C3F/C6F)-Crp (AV066139) and (C3F/C-
4F/C5S/C6F)-Crp (AV070606) mutants would lack all disul-
fides typical of -defensins. Although the actual disulfide con-
nectivities in these deduced Crp mutants are unknown,
especially in vivo, our findings predict that the -defensin
component of these expressed proforms would be degraded
during MMP-7-mediated activation. Given the demonstrated
impact of Paneth cell -defensins on enteric immunity (3), a
loss of function caused by MMP-7- or trypsin-mediated prote-
olysis of naturally occurring -defensin disulfide mutants could
have adverse consequences for innate immunity in the small
intestine.
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